Baidu
map

Boston Immune与百济神州签订**选择权和许可协议,以开发新型TNFR2抗体

2021-02-18 Allan MedSci原创

波士顿免疫技术和治疗公司(Boston Immune)今天宣布,已和百济神州签订独家选择权和许可协议,旨在开发和商业化Boston Immune的创新性肿瘤坏死因子(TNF)受体2(TNFR2)抗体。

波士顿免疫技术和治疗公司(Boston Immune)今天宣布,已和百济神州签订独家选择权和许可协议,旨在开发和商业化Boston Immune的创新性肿瘤坏死因子(TNF)受体2(TNFR2)抗体。百济神州已获得在亚洲(不包括日本)、澳大利亚和新西兰开发、生产和商业化TNFR2抗体(BITR2101)的独家许可。两家公司计划进行BITR2101的I期临床试验,包括与百济神州的抗PD-1抗体tislelizumab的组合。

Boston Immune首席执行官Russell LaMontagne表示:“百济神州是一家拥有出色业绩的全球制药公司,是帮助开发研究性TNFR2抗体BITR2101的理想合作伙伴。与百济神州的合作是对Boston Immune抗体平台的有力验证,并且有机会证明BITR2101作为单一药物以及与免疫检查点抑制剂tislelizumab联合使用的潜力”。

TNFR2是TNF受体超家族的成员,它在许多肿瘤类型上高表达,并已显示出可促进肿瘤细胞生长。 TNFR2还表达在肿瘤微环境中的抑制性免疫细胞上,包括调节性T细胞(Tregs)和髓样来源的抑制性细胞。TNFR2已被确定为免疫逃逸和肿瘤发展以及免疫检查点抑制剂耐药性的潜在驱动力。

 

原始出处:

https://www.firstwordpharma.com/node/1801851?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=972419, encodeId=71bb9e241942, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELcs5XYFut6ZAZYKOyZF6dDtrLwEgcbMmOjm8J3REzATGJTm5FfQzSpAdFqnvKToXyO50SwvbibOAw/132, createdBy=7bec2044055, createdName=1351ea501bm, createdTime=Thu Jun 10 10:02:46 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401791, encodeId=70a31401e91cd, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Sat Feb 20 00:12:41 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519415, encodeId=400c15194159e, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 20 00:12:41 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925214, encodeId=81f592521404, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Feb 18 09:37:41 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925211, encodeId=ae59925211f3, content=病毒在变异, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200914/f1df8506d5cb4909bac2efc340b6c1fe/dcc6dd2dbec44613838b555fbe723804.jpg, createdBy=686b1371609, createdName=liyu7822, createdTime=Thu Feb 18 09:20:12 CST 2021, time=2021-02-18, status=1, ipAttribution=)]
    2021-06-10 1351ea501bm

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=972419, encodeId=71bb9e241942, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELcs5XYFut6ZAZYKOyZF6dDtrLwEgcbMmOjm8J3REzATGJTm5FfQzSpAdFqnvKToXyO50SwvbibOAw/132, createdBy=7bec2044055, createdName=1351ea501bm, createdTime=Thu Jun 10 10:02:46 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401791, encodeId=70a31401e91cd, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Sat Feb 20 00:12:41 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519415, encodeId=400c15194159e, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 20 00:12:41 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925214, encodeId=81f592521404, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Feb 18 09:37:41 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925211, encodeId=ae59925211f3, content=病毒在变异, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200914/f1df8506d5cb4909bac2efc340b6c1fe/dcc6dd2dbec44613838b555fbe723804.jpg, createdBy=686b1371609, createdName=liyu7822, createdTime=Thu Feb 18 09:20:12 CST 2021, time=2021-02-18, status=1, ipAttribution=)]
    2021-02-20 snowpeakxu
  3. [GetPortalCommentsPageByObjectIdResponse(id=972419, encodeId=71bb9e241942, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELcs5XYFut6ZAZYKOyZF6dDtrLwEgcbMmOjm8J3REzATGJTm5FfQzSpAdFqnvKToXyO50SwvbibOAw/132, createdBy=7bec2044055, createdName=1351ea501bm, createdTime=Thu Jun 10 10:02:46 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401791, encodeId=70a31401e91cd, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Sat Feb 20 00:12:41 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519415, encodeId=400c15194159e, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 20 00:12:41 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925214, encodeId=81f592521404, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Feb 18 09:37:41 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925211, encodeId=ae59925211f3, content=病毒在变异, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200914/f1df8506d5cb4909bac2efc340b6c1fe/dcc6dd2dbec44613838b555fbe723804.jpg, createdBy=686b1371609, createdName=liyu7822, createdTime=Thu Feb 18 09:20:12 CST 2021, time=2021-02-18, status=1, ipAttribution=)]
    2021-02-20 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=972419, encodeId=71bb9e241942, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELcs5XYFut6ZAZYKOyZF6dDtrLwEgcbMmOjm8J3REzATGJTm5FfQzSpAdFqnvKToXyO50SwvbibOAw/132, createdBy=7bec2044055, createdName=1351ea501bm, createdTime=Thu Jun 10 10:02:46 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401791, encodeId=70a31401e91cd, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Sat Feb 20 00:12:41 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519415, encodeId=400c15194159e, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 20 00:12:41 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925214, encodeId=81f592521404, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Feb 18 09:37:41 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925211, encodeId=ae59925211f3, content=病毒在变异, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200914/f1df8506d5cb4909bac2efc340b6c1fe/dcc6dd2dbec44613838b555fbe723804.jpg, createdBy=686b1371609, createdName=liyu7822, createdTime=Thu Feb 18 09:20:12 CST 2021, time=2021-02-18, status=1, ipAttribution=)]
    2021-02-18 yangchou

    好文章,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=972419, encodeId=71bb9e241942, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELcs5XYFut6ZAZYKOyZF6dDtrLwEgcbMmOjm8J3REzATGJTm5FfQzSpAdFqnvKToXyO50SwvbibOAw/132, createdBy=7bec2044055, createdName=1351ea501bm, createdTime=Thu Jun 10 10:02:46 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401791, encodeId=70a31401e91cd, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Sat Feb 20 00:12:41 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519415, encodeId=400c15194159e, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 20 00:12:41 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925214, encodeId=81f592521404, content=好文章,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Thu Feb 18 09:37:41 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925211, encodeId=ae59925211f3, content=病毒在变异, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200914/f1df8506d5cb4909bac2efc340b6c1fe/dcc6dd2dbec44613838b555fbe723804.jpg, createdBy=686b1371609, createdName=liyu7822, createdTime=Thu Feb 18 09:20:12 CST 2021, time=2021-02-18, status=1, ipAttribution=)]
    2021-02-18 liyu7822

    病毒在变异

    0

相关资讯

NMPA批准百济神州的抗PD-1单抗替雷利珠,用于治疗局部晚期或转移性尿道上皮癌

替雷利珠单抗(tislelizumab)获NMPA批准,用于PD-L1高表达、在含铂化疗期间或之后或在新辅助或含铂化疗辅助治疗的12个月内疾病进展的局部晚期或转移性尿路上皮癌(UC)患者。

百济神州宣布,抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者,3期试验达到无进展生存的主要终点

百济神州宣布其抗PD-1单抗替雷利珠单抗联合培美曲塞和铂类化疗,用于一线治疗非鳞状非小细胞肺癌(NSCLC)患者的3期试验达到了其主要终点--无进展生存期(PFS)在统计学上有显着改善。

诺华支付6.5亿美元用于百济神州抗PD-1药物tislelizumab的海外使用权

诺华公司本周一宣布,诺华已与百济神州签署了一项战略协议,已获得中国以外的几个主要市场的tislelizumab销售权。

ASCO 2020:肺鳞癌免疫治疗新突破,百济神州展现中国“研”值

2020年5月29日,全球肿瘤界的年度盛会——美国临床肿瘤学会(ASCO)年会正式揭开序幕。

百济神州PD-1单抗Tislelizumab治疗肝细胞癌的新药申请被NMPA接受,以及Tislelizumab抗肿瘤临床研究汇总

“世界上一半的肝癌患者都居住在中国,医疗需求仍未得到满足。”

Blood:BTK抑制剂泽布替尼治疗华氏巨球蛋白血症的疗效

华氏巨球蛋白血症(WM)是一种罕见的非霍奇金淋巴瘤,淋巴浆细胞淋巴瘤。泽布替尼是中国百济神州公司自主研发的一种选择性BTK抑制剂,旨在评估泽布替尼用于WM的疗效。

拓展阅读

总生存期近17个月!BMJ:这类胃癌患者治疗获益更大,死亡风险更低

研究表明抗PD-1抗体tislelizumab联合化疗治疗局部晚期不可切除或转移性胃或胃食管交界处腺癌,患者可获得更高的总生存期,且安全性可控。

百济神州的tislelizumab在中国再次获得批准

与化疗相比,tislelizumab 可将 ESCC 患者的死亡风险降低 30%。

Clin Cancer Res:Tislelizumab治疗复发/难治性经典霍奇金淋巴瘤的长期预后

Tislelizumab对复发性/难治性cHL患者具有长期的生存益处和良好的安全性

诺华支付6.5亿美元用于百济神州抗PD-1药物tislelizumab的海外使用权

诺华公司本周一宣布,诺华已与百济神州签署了一项战略协议,已获得中国以外的几个主要市场的tislelizumab销售权。

2019年ESMO亚洲大会:百济神州发表有关Tislelizumab的临床数据

百济神州制药公司是一家商业阶段的生物制药公司,致力于开发和商业化用于治疗癌症的新型分子靶向和免疫肿瘤药物,近日宣布了来自II期临床的初步临床数据,该研究是抗PD-1抗体Tislelizumab联合化疗在胃/胃食管交界处(G / GEJ)腺癌或食道鳞状细胞癌(ESCC)患者中进行的试验。

Baidu
map
Baidu
map
Baidu
map